spacer
home > pmps > winter 2003 > take the hassle out of buying a vessel
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Take the Hassle Out of Buying a Vessel

Purchasing new process vessels for the pharmaceutical industry is often a time-consuming and onerous task. The industry is required to ensure that their new equipment meets with current legislation, operating procedures and approvals, as well as ensuring that any ancillary equipment is fully integrated for successful operation.

For process engineers wishing to purchase a new vessel there are a number of procedures to go through before a vessel and any ancillary equipment is fully operational. These procedures can be very time consuming, and if not administered correctly can create unnecessary delays and hassle. This article breaks these procedures down into categories and also indicates the best methods that engineers should adopt when purchasing new vessels.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Paul Mayer, Sales Director at Braby

A qualified Mechanical Engineer, Paul Mayer's first position was as a Production Engineer in a large UK print engineering company. He soon progressed to managing the production area responsible for the co-ordination of the entire plant manufacturing process. After several years, and following a period of skills training, Paul assumed the role of Commercial Manager for the same organisation working with a large international customer base. This lead to his appointment as Head of the sales force, which covered most of the world market. Paul joined Braby in 1997 and managed the sales force becoming Director of Sales and Marketing. He and his team have lead Braby into many new market areas and developed the single source approach for prospective customers.

spacer
Paul Mayer
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Avacta develops SARS-COV-2 neutralising Affimer reagents with therapeutic potential for COVID-19

Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, is pleased to announce that several of the Affimer reagents recently generated for development of a point-of-care COVID-19 antigen saliva test have now also been shown to block the interaction between the virus’ spike protein and ACE2, a receptor on human cells that is key to the virus infection pathway1.
More info >>

White Papers

What is process characterization?

EXPUTEC

Process characterization is an essential step in the commercialization of a new (biological) drug. For drug product commercialization, manufacturers must validate the drug’s manufacturing process. This ensures that the manufacturing process delivers consistently a quality product and that the patient is not at risk.
More info >>

 
Industry Events

INTERPHEX 2020

15-17 July 2020, Javits Center NYC


More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement